New Analyses for Phase 3 Lenvatinib SELECT Study
the Cancer Therapy Advisor take:
According to a new analysis from the Phase 3 SELECT trial, which studied lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer, the level of baseline angiopoietin-2 may be able to be used as a predictive factor for lenvatinib response. Angiopoietin-2 is a protein that plays a role in angiogenesis.
Another analysis from the study demonstrated a statistically significant association between hypertension and progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer being treated with lenvatinib. Hypertension is a typical adverse effect associated with vascular endothelial growth factor receptor (VEGFR) inhibition, as well as a biomarker for tyrosine kinase inhibitor (TKI) effectiveness in patients with renal cell carcinoma. In the SELECT study, researchers observed an incidence of hypertension in 73% of patients treated with lenvatinib.
A third analysis found that patients treated with lenvatinib for 1 year or more experienced a rapid tumor shrinkage within the first 8 weeks of treatment followed by a slower, continuous tumor shrinkage. In addition, findings being presented at the European Society for Medical Oncology 2014 Congress in Madrid, Spain, demonstrated a consistent progression-free survival benefit in all subgroups of the patient population examined.
Baseline angiopoietin-2 may be a predictive factor for lenvatinib response in endocrine cancer.
A new analysis from the Phase III SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) trial of lenvatinib (E7080) in the treatment of radioiodine-refractory differentiated thyroid cancer shows that the level of baseline angiopoietin-2 may be a predictive factor for lenvatinib response and therefore tumour shrinkage and prolonged progression free survival (PFS). Angiopoietin-2 is a protein which regulates the formation of new blood vessels in tumours.
A second analysis from SELECT shows a statistically significant correlation between hypertension and PFS in people with radioiodine-refractory differentiated thyroid cancer. Hypertension is a known adverse event of vascular endothelial growth factor receptor (VEGFR) inhibition and a biomarker for tyrosine kinase inhibitor efficacy in renal cell carcinoma treatment. In the SELECT study, 73% of lenvatinib treated patients experienced hypertension.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy